Genenta Science S.p.A. is a clinical-stage biotechnology company developing hematopoietic stem cell gene therapies for the treatment of solid tumors. The company's lead product candidate is Temferon, in Phase 1/2a clinical trials for the treatment of glioblastoma multiforme in patients with an unmethylated MGMT gene promoter. Genenta Science was incorporated in 2014 and is headquartered in Milan, Italy.
Name / Ticker | Price | Zen Rating |
---|---|---|
$2.58 | A | |
$8.46 | A | |
$126.40 | A |